# DAFTAR PUSTAKA

Agilent Technologies Inc., 2012. Introduction to Quantitative PCR, USA: Agilent technology Inc.

Albertini, M.C., Fabiola, O., Raffaella, L., Francesca, P., Francesco, G., Giorgio, S., Augusto, A., Maria, R., and Antonio, D., 2011, "Predicting microRNA Modulation in Human Prostate Cancer Uing a Simple String Identifier", *J Biomed Inform*, 44, 615-620.

American Cancer Society, 2017, Prostate Cancer. <https://www.cancer.org/cancer/prostate-cancer.html>. (diakses 23 Oktober 2017).

Blondal, T., Jensby, N., Baker, A., Andreasen, D., Mouritzen, P., Wrang, T., Dahlsveen I., 2012, "Assesing Sample and miRNA Profile Quality in Serum and Plasma or Other Biofluid", *Method*, 59, S1-S6.

Chang, C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., 2011, "p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs", *Nat Cell Biol.*, 13, 1467.

Chmelar, R., Buchanan, G., Need, E.F., Tilley W., Greenberg, N.M., 2007, "Androgen Receptor Coregulators and Their Involvement In The Development and Progression of Prostate Cancer", *Int. J. Cancer*, 120, 719–733.

Chuang, A.Y., DeMarzo, A., Veltri, R.W., Sharma, R., Bieberich, C., and Epstei, J., 2017, "Immunohistochemical differentia- tion of high-grade prostate carcinoma from urothelial carcinoma", *Am J Surg Pathol.*, 31, 1246–55.

Detassis, S., Margherita G., Valerio D.V., and Michela A.D., 2017, "microRNAs Make The Call In Cancer Personalized Medicine", *Front. Cell. Dev. Biol.*, 5, 86.

Egidi, M.G., Giovanni C., Gabriella G., Danilo Z., Silvana D., Giulia P., and Ettore M., 2015, "Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications", *Hindawi*, Vol.2015.

Epstein, M. J. Zelefsky, and D. D. Sjoberg, 2016, "Acontemporary prostate cancer grading system: a validated alternative to the *Gleason Score*", *Eur Urol*, 69, 428–435.

Escola, J.M., M.J. Kleijmeer, W., Stoorvogel, J.M. Griffith, O. Yoshie, and H.J. Geuze,1998, "Selective Enrichment Of Tetraspan Proteins On The Internal Vesicles Of Multivesicular Endosomes and On Exosomes Secreted By Human B-lymphocytes", *Biol Chem*, 273, 0121–20127.

Esteller, M., 2008, "Epigenetics in Cancer", *N. Engl. J. Med.*, 358, 1148–1159.

Fan, Y.,Shenyi, Y., Yang Hao, Junyu, Y., Hanshuo, Z., Changhong, S., Ming Ma, Qing Chang, and Jianzhong, J., 2014, "miR-19b Promotes Tumor Growth and Metastasis Via Targeting TP53", *RNA*, 20, 765-772.

Fredsøe, J., Anne,K., Anni, R., Peter, M., Søren, H., Michael, B., Torben, F., and Karina, D., 2017, "Diagnostic and prognostic MicroRNA biomarker for prostate cancer in cell-free urine", *Eur Urol Foc*, 297, 9.

Fuziwara, Cesar S., and Kimura Edna T., 2015, "Insight into Regulation of the miR-17-92 cluster of miRNAs in cancer", *Front Med*, 2, 64.

Garibaldi, F., Falcone, E., Trisciuoglio, D., Colombo, T., Lisek, K., Walerych, D., Sal, G. Del., Paci, P., Bossi, G., Piaggio, G., and Gurtner, A., 2016, "Mutant p53 Inhibits miRNA Biogenesis by Interfering With The Microprocessor Complex", *Oncogene*, 1-11.

Genecards, 2017, MIR19B1 Gene. < http://www.genecards.org/cgi bin/carddisp.pl?gene= MIR19B1&keywords=mir-19b-3p>. (diakses 25 Oktober 2017).

Globocan, 2012, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. <http://globocan.iarc.fr/Pages/online.aspx>. (diakses 22 Oktober 2017).

Han, Y.C., Vidigal J.A., Mu P., Yao E., Sing H.I., Gonzalez A.J., 2015, "An allelic series of miR-17 approximately 92-mutant mice uncovers functional specialization and cooperation among members of a micro RNA polycistron", *Nat. Genet*, 47(7), 766–75.

Haoran, Ll and Burton, B.Y., 2013," Friend or Foe : The Role of microRNA in Chemoterapy Resistance", *Acta Pharmacologica Sinica*, 34, 870-879.

Hessvik, N.P., and Llorente, A., 2017, "Current Knowledge On Exosome Biogenesis and Release", *Cell Mol. Life Sci*.

Heyns, M. Fisher, A. Lecuona, and A. Van der Merwe, 2011, "Prostate cancer among different racial groups in the western cape: presenting features and management", *S. Afr. Med. J.*, 101(4), 267–270.

Ho, C.K., and Habib, F.K, 2011, "Estrogen and Androgen Signaling in The Pathogenesis Of BPH". *Nat. Rev.Urol.*, 8(1), 29-41.

Ho, M.Y., and John R.M., 2014," Presentation and management of docetaxel-related adverse effect in patient with breast cancer", *Cancer management and research*, 6, 253-259.

Hoffman, A.E., Zheng, T., Yi, C., Leaderer, D., Weidhaas, J., Slack, F., 2009, "microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis", *Int. J. Cancer Res*, 69, 5970–5977.

Homma, Y., Gotoh, M., Yokoyama, O., 2011, "Outline of JUA Clinical Guidelines For Benign Prostatic Hyperplasia", *Int J Urol*,. 18(11), 741-756.

Hühn, D., Kousholt A.N., Sørensen C.S., Sartori A.A., 2015, "miR-19, a component of the oncogenic miR-17_92 cluster, targets the DNA-end resection factor CtIP." *Oncogene*, 34 (30), 3977–84.

Huotari, J., and Helenius, A., 2011, "Endosome Maturation", *The EMBO Journal*, 30, 3481–3500.

Hu, Z., Chen, J., Tian, T., Zhou, X., Gu, H., Xu, L., 2008, "Genetic variants of miRNA sequences and non-small cell lung cancer survival", *J. Clin. Invest*, 118, 2600–2608.

Jackson, B.L., Anna, G., Hari, L.R., 2014, "MicroRNA in prostate cancer: Functional importance and potential as circulating biomarker", *BioMed Central*, 14, 930.

Kapoor, A., 2012, "Benign Prostatic Hyperplasia (BPH) Management In The Primary Care Setting", *Can. J. Urol*. 9, 10-17.

Karan, D., J. Thraser, and D. Lubaroff, 2008, "Prostate Cancer Genes, Environment, Immunnity and The Use Of Immunotherapy", *Prostate Cancer Prostatic dis.*, 11 (3), 230-236.

Kawahara, Yukio, 2014, "Human Disease Caused by Germline and Somatic Abnormalities microRNA and microRNA-related genes", *Congenital Abnormalies*, 54, 12-21.

KEGG, 2017, Prostate Cancer-Reference Pathway. <http://www.genome.jp/kegg-bin/show_pathway?map05215>. (Diakses 23 Oktober 2017).

Kementerian Kesehatan, 2013, Riset Kesehatan Dasar 2013, Badan Penelitian dan Pengembangan Kementerian Kesehatan RI.

Kgatle, M.M., Asgar, A.K., Muhammed, M., Mike, S., and Razia, M., 2016, "Prostate Cancer : Epigenetic Alteration, Risk Factor, and Therapy", *Hindawi*, 2016, 1-11.

Kim, S.B., Cho, I.C., Min, S.K., 2014, "Prostate Volume Measurement By Transrectal Ultrasonography: Comparison Of Height Obtained By Use Of Transaxial and Midsagittal Scanning", *Korean Journal of Urology*, 55(7), 470-474.

Kowal, J., Mercedes, T., and Clotilde, T., 2014, "Biogenesis and Secretion Of Exosome", *Current Opinion in Cell Biology*, 29, 116-125.

Lark, A.L., Livasy C.A., Dressler L., Moore D.T., Millikan R.C., Geradts J., 2005, "High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype", *Mod. Pathol.*18, 1289–94.

Leaderer, D., Aaron E.H., Tongzhang Z., Alan F., Joanne W., Trupti P., and Yong Z., 2011, "Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis", *Int. J. Mol. Epidemiol. Genet*, 1, 9-18.

Lee, H.W., Kim, S.A., Nam, J.W., 2014, "The Study About Physical Activity For Subjects With Prevention Of Benign Prostate Hyperplasia", *Int Neurourol J*,18(3), 155-162.

Lin, J., and Redies, C., 2012," Histological Evidence Housekeeping Genes Beta-actin and GAPDH are of Limited Value For Normalization of Gene Expression", *Development Gene and Evolution*, 222, 369-376.

Lipski, R.I. Garcia, and Brawer, 1996, "Prostatic intraepithelial neoplasia: significance and management", *Seminars in Urologic Oncology*, 14(3),149–155.

Livak, K.J., and Schmittgen, T.D., 2001, "Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and The $2^{-\Delta\Delta CT}$ Method", *Method*, 25, 402-408.

McGuire, A., Brown, J.A.L., Kerin M.J., 2015, "Metastatic Breast Cancer: The Potential of miRNA for Diagnosis and Tratment Monitoring", *Cancer Metastasis Rev*., 34, 145-155.

Mehrain, Y., Irene S., Marlene E., Jürgen K., and Ortrud K.S., 2015, "DICER1 Syndrome Can Mimic Different Genetic Tumor Predispositions", *Cancer Letters*, 370, 275-278.

Mehra, R., Tomlins, S., Yu, J., Cao, X., Wang, L., Menon, A., Rubin, M.A., Pienta, K.J., Shah, R.B., and Chinnaiyan, A.M., 2008, "Characterization of TMPRSS2-

ETS gene aberrations in androgen-independent meta- static prostate cancer", Int J *Cancer Res*, 68, 3584–90.

Meshkat, M., Tanha, H.M., Naeini, M.M., Ghaedi, K., Sanati, M. H., 2016, "Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival", *Cancer Biomarkers*, 17, 213–222.

Miranda, K.C., Daniel T.B., Mary McKee, Johan S., Teodor G.P., Nicolas Da Silva, Dennis B., and Leileata M.R., 2010, "Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease", *Int. Society of Nephrology*, 78, 191-199.

Mirbase, 2017, Stem Loop Sequence Has-miR-19b-1. <http://www.mirbase.org/cgi-bin/mirna_ entry.pl?acc=MI0000074>. (Diakses 25 Oktober 2017).

Mirtarbase,2017, miRTarBase. < http://mirtarbase.mbc.nctu.edu.tw/php/search.php >. (Diakses 25 Oktober 2017).

Mitchell, P.J., Welton, J., Staffurth, J., 2009, "Can urinary exosomes act as treatment response
markers in prostate cancer?", *J Trasl Med Epidemiol.*,7(4).

Muller P.A., and Vousden K.H., 2014, "Mutant p53 in cancer: new functions and therapeutic opportunities", *Cancer Cell*, 25, 304–317.

Muller, P.A., Vousden K.H., Norman J.C., 2011, "p53 and its mutants in tumor cell migration and invasion", *J. Cell. Biol*., 192, 209–18.

Nelson WG, De Marzo AM, Deweese TL, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001;952:135–44.

Olive, V., Jiang I., He L, 2010," Mir-17-92, a Cluster of miRNAs In The Midst of The Cancer Network", *J. Biochem. Cell. Biol.*, 42, 1348-1354.

Osip'yants, A.I., Knyazev, E., Galatenko, E., Nyushko, K., Galatenko, V.V., Shikurnikov, M., and Alekseev, B., "Changes in the level of circulating hsa-miR-297 and hsa-miR-19b-3p miRNA are associated with generalization of prostate cancer", 162 (9), 366-369.

Parsons, J.K., 2010, "Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors", *Curr Bladder Dysfunct Rep*., 5(4), 212-218.

Patnaik, S.K., Eric Kannisto, Steen K., and Sai Y., 2010 "Evaluation of MicroRNA Expresion Profiles That May Predict Recurrence of Localized Stage I Non-Small Cell Lung Cancer After Surgical Resection", *American Association For Cancer Research*, 70 (1).

Pawson T., and Nash P., 2000, "Protein–protein interactions define specificity in signal transduction", *Genes Dev.*,14, 1027–47.

Pfeffer, S.R., 2010, "Two Rabs For Exosome Release", *Nat. Cell Biol*, 12(1).

Pienta, K.J, 2001, "Preclinical Mechanism of Dcetaxel combination in prostate cancer", *Seminar in Oncology*, 20(4), 3-7

Pisitkun, T., Shen R.F., Knepper M.A.,2004, "Identification and Proteomic Profiling Of Exosomes In Human Urine", *Proc Natl Acad Sci USA*,101, 13368–13373.

Rakheja, D., Kenneth S.C., Yangjian L., Abhay A., Shukla, Vanessa S., Tsung-Cheng C., Shama K., Jonathan E.W., Nitin J.K., James S.M., Joshua T.M., and James F.A., 2014, "Somatic Mutations in DROSHA and DICER1 Impair microRNA Biogenesis Through Distinct Mechanisms in Wilms Tumours", *Nat Commun*, 5, 4802.

Reboucas, E., Costa J.J., Passos, M.J., Passos, J.R., van den Hurk, R., and Silva, J.R.V., 2013, "Real Time PCR and Importance of Housekeeping Genes for Normalization and Quantifcation of mRNA expression in Different Tissue", *Braz. Arch. biol. technol.*, 56(1), 143-154.

Rutnam, Z.J., Wight T.N., and Yang B.B, 2012, " miRNA Regulate Expression and Function of Ecxtracellular Matrix Molecules", *Matrix Biol*., 32, 74-85.

Sato-Kuwabara, Y., Melo, S.A., Soares, F.A., Calin, G.A., 2015, "The fusion of two worlds: non-coding RNAs and extracellular vesicles – diagnostic and therapeutic implications", *Int Jl Oncol*, 46, 17–27.

Sausville, J., and Naslund, M., 2010, "Benign Prostatic Hyperplasia and Prostate Cancer: An Overview For Primary Care Physicians", *Int J Clin Pract Suppl*, 2010, 64(13), 1740-1745.

Scheel, C., Weinberg R.A., 2012, "Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links", *Semin. Cancer Biol*,. 22, 396–403.

Schrecengost, R., and Knudsen, E., 2013, "Molecular Pathogenesis and Progression of Prostate Cancer", *Journal Seminars in Oncology*, 40, 244-258.

Shan, S.W., Lee D.Y., Deng Z., Shatseva T., Jeyapalan Z., Du W.W., 2009, " microRNA miR-17 Retard Tissue Growth and Represses Fibronectin Expression", *Nat. Cell. Biol.*, 11, 1031-1038.

Shen, Jia, Weiya Xia, Yekka T., Khotskaya *et al*., 2013, " EFGR Modulates microRNA Maturation in Response to Hypoxia Through Phosporylation of AGO2", *Nature*, 000, 1-5.

Sherr, C.J., Weber J.D., 2000, "The ARF/p53 pathway", *Curr. Opin. Genet. Dev.*, 10, 94–9.

Shin, I., Yakes F.M., Rojo F., 2002, " PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization", *Nat Med*, 8,1145–52.

Shoman, N., Shannon K., Andrew McFadden, and Mikelis G.B., 2005, "Reduced PTEN Expression Predicts Relapse in Patients With Breast Carcinoma Treated by Tamoxifen", *Mod Pathol*, 18, 250-259.

Siegel, D. Naishadham, and A. Jemal, 2013, "Cancer statistics, 2013", *CA Cancer J Clin*, 63(1), 11–30.

Silva, M.P., João D.B.S., Elin E., Wanja K., Tarjei S.H., Manohar P., Joana V., Manuel R.T., and Havard E.D., 2016, " Prostate Cancer Prognosis Defined by The Combined Analysis of 8q, PTEN and ERG", *Translational Oncology*, 9(6), 572-582.

Skog, J., Tom W., Sjoerd V.R., Dimphna M., Laura G., Miguel Sena-Esteves, William T.C., Robert S., Anna M.K., and Xandra O.B., 2008, "Glioblastoma Microvesicles Transport RNA and Protein That Promote Tumor Growth and Provide Diagnostic Biomarkers", *Nat. Cel.l Biol.*, 10(12), 1470-1476.

Stenmark, H., 2009 "Rab GTPases As Coordinators Of Vesicle Traffic. *Nat Rev Mol Cell Biol.*,10, 13-525.

Stuopelyte, Kristina, Kristina Daniunaite, Arnas Bakavicius, Juozas R Lazutka, Feliksas Jankevicius, and Sonata Jarmalaite, 2016, "Detection of miRNA in Urine of Prostate Cancer Patient", *Medicina*, 116–124.

Stuopelyte, Kristina, Kristina Daniunaite, Arnas Bakavicius, Juozas R Lazutka, Feliksas Jankevicius, and Sonata Jarmalaite, 2016, "The Utility of Urine-Circulating miRNAs for Detection of Prostate Cancer", *Br. J Cancer*, 1-9.

Tee, A.R., Fingar D.C., Manning B.D., 2002, "Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling", *Proc Natl Acad Sci USA*, 99, 13571–6.

Testa, J.R., Bellacosa A., 2001, "AKT plays a central role in tumorigenesis", *Proc Natl Acad Sci USA*, 98,10983–5.

Tian, L., Yu-Xiang F., Jing-Lun X., Jin-Zhong C., 2013, "Four miRNA Promote Prostat Cell Proliferation with Regulation of PTEN and its downstream signal in vitro", *PLoS ONE*, 8(9), e 75885.

Valadi, H., K. Ekström, A. Bossios, M. Sjöstrand, J.J. Lee, and J.O. Lötvall, 2007, "Exosome Mediated Transfer Of mRNAs and microRNAs Is a Novel Mechanism Of Genetic Exchange Between Cells. *Nat. Cell Biol*, 9, 654–659.

Van, Niel G., I. Porto-Carreiro, S. Simoes, and G. Raposo, 2006, "Exosomes: a Common Pathway For a Specialized Function", *Int. J. Biochem. Cell Biol*., 140, 13–21.

Vara, J.A.F., Enrique C., and Javier de C., 2004, "PI3K/Akt Signalling Pathway and Cancer", *Cancer Treatment Reviews*, 30, 193-204.

Velcheti, V., Satish, K., Stephen, F., Om, P., 2008, " Pathogenesis of Prostate Cancer: Lessons From Basic Research", *The Ochsner Journal*, 8, 213-218.

Wang, L., Hua X., Fengxia W., Yingjie Z., Ji Wang, Xiaolan G., Li-Ju C., Yong Z., M. James Y., Shahriar K., Mohammad S., Haojie H., Junxuan L., and Yibin D., 2014, "Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth", *Cell Rep*, 8, 1461-1474.

Wang, S., Garcia, A.J., Wu, M., Lawson, D.A., Wittle, O., and Wu, H., 2006, "Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation", *Proc Natl Acad Sci USA*,103, 1480–5.

Wang, Siao-Yi., Stephen, S., Cassandra, D., Matthew, R., Jeffrey, P., Hubert, S., Janet, C., Peter, R., and Robert, B., 2014, "miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance", *PLoS ONE*, 9(6), e98597.

Wubbolts, R., R.S. Leckie, P.T. Veenhuizen, G. Schwarzmann, W. Möbius, J. Hoernschemeyer, J.W., Slot, H.J., Geuze, and W. Stoorvogel, 2003, "Proteomic and Biochemical Analyses of Human B Cell-Derived Exosomes, Potential Implications for Their Function and Multivesicular Body Formation", *J Biol Chem*, 278, 10963–10972.

Xia, M., and Hartmut L., 2007, " Tumor Suppressor p53 Restrict Ras Stimulation Of RhoA and Cancer Cell Motility", *Nat. Struct. mol. Biol.*, 14, 3.

Yang, Zhong-Hua, Xing-Huan, W., Huai-Peng, W., and Li-Quan Hu., 2009, "Effect of TRPM8 on The Proliferation and Motility of Prostate Cancer PC-3 Cells", *Asian J Androl*, 11, 157-165.

Yee, Jie Yin, Lie M.G., Keith R., Susan M.R., Vanessa S.Y., and Edmund J.D.L., 2014, " Ensuring Good Quality RNA For Quantitative Real-Time PCR Isolated From Renal Proximal Tubular Cells Using Laser Capture Microdissection", *Biomed Central*, 7, 62.

Zhang, X.A., He B., Zhou B., Liu L., 2003, "Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration". *J Biol Chem.*, 278, 27319–28.